Last checked at 18 Aug 2022 07:00
18 August 2022
PureTech Health plc
Transaction in Own Shares
PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.
Date of purchase: | 17 August 2022 |
Number of ordinary shares purchased: | 33 |
Highest price paid per share: | 244.50p |
Lowest price paid per share: | 244.50p |
Volume weighted average price paid per share: | 244.50p |
PureTech intends to retain the purchased shares in treasury.
Following the above transaction, the Company will have 4,369,169 ordinary shares in treasury and has 284,320,281 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 284,320,281, which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders.
This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Annual Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.
For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com
Individual Transactions
Transaction Date | Transaction Time | Volume | Price (GBp) | Platform | Transaction Reference Number |
17/08/2022 | 8:50:24 | 33 | 244.5 | AQXE | 00313387228TRLO1.1.1 |